Healthcare firm Personalis beats Q3 revenue estimates

Personalis

04/11/2025 21:27

Overview

Personalis Q3 revenue beats analyst expectations despite a 44% yr/yr decline

Net loss for Q3 2025 was $21.7 mln, compared to $39.1 mln last year

Clinical test volume grows 364% yr/yr, driven by NeXT Personal platform adoption

Outlook

Personalis expects Q4 2025 revenue between $15.7 mln and $20.7 mln

Full-year 2025 revenue guidance revised to $68.0 mln to $73.0 mln

Company maintains full-year gross margin guidance at 22% to 24%

Result Drivers

CLINICAL TEST GROWTH - Clinical test volume grew 364% yr/yr, driven by increased adoption of NeXT Personal platform

LUNG CANCER DATA - Presentation of positive data from AstraZeneca's NeoADAURA trial and LAURA trial supports NeXT Personal's effectiveness in lung cancer

BREAST CANCER STUDY - Launch of CATE trial with Yale Cancer Center aims to demonstrate NeXT Personal's utility in HR+/HER2- breast cancer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$14.49 mln
$13.30 mln (7 Analysts)
Q3 Net Income
-$21.65 mln
Q3 Basic EPS
-$0.24
Q3 Income From Operations
-$23.29 mln
Q3 Pretax Profit
-$21.64 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Personalis Inc is $7.00, about 28.6% below its November 3 closing price of $9.00

Press Release: ID:nBw3J1vJ2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)